Tizanidine ( DrugBank: Tizanidine )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎3

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00464958
(ClinicalTrials.gov)
January 200822/4/2007One Year Extension Study To Protocol C2/5/TZ:MS-05Long Term Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in Patients With Multiple Sclerosis - Open Label Extension StudySpasticity;Multiple SclerosisDrug: sublingual tizanidine 12 mgTeva GTCNULLTerminated20 Years65 YearsBoth10Phase 1/Phase 2Israel
2NCT00358293
(ClinicalTrials.gov)
December 200627/7/2006Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant SpasticityA Double-Blind, Randomized, Crossover Study to Evaluate the Clinical Efficacy and Safety of Oral Tizanidine HCl (12 mg) Versus Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in MS PatientsMuscle SpasticityDrug: Tizanidine (sublingual or oral)Teva GTCNULLCompleted20 Years65 YearsBoth20Phase 1/Phase 2Israel
3NCT00047580
(ClinicalTrials.gov)
June 20028/10/2002Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.A Multicenter, Open-Label, Randomized, 4-Way Crossover Trial of the Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex (Tizanidine Hydrochloride) Tablets Taken Under Fed and Fasted Conditions in Patients With Moderate to Severe SpasticityMultiple Sclerosis;Muscle Spasticity;Spinal Cord Injury;StrokeDrug: tizanidine hydrochloride capsuleElan PharmaceuticalsNULLCompleted18 YearsN/ABoth120Phase 3United States